This article is more than 5 years old. Information may no longer be current.

Congenital adrenal hyperplasia therapy granted orphan drug status

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has granted orphan drug status to Neurocrine Biosciences, Inc., for NBI-77860, a proprietary corticotropin releasing factor 1 receptor antagonist for the treatment of congenital adrenal hyperplasia.

“We are very pleased that the FDA has granted NBI-77860 orphan status to treat congenital adrenal hyperplasia, a devastating disease that is a significant challenge for both clinicians and patients,” Malcolm Lloyd-Smith, chief regulatory officer or Neurocrine Biosciences, said in the release. “This status represents a significant regulatory milestone for the [congenital adrenal hyperplasia] program and underscores that importance of bringing a safe and effective [congenital adrenal hyperplasia] therapy to market. We look forward to the results from our recently initiated 1401 Study of adolescents with class [congenital adrenal hyperplasia], in 2015.”